The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

Completed · Phase 2 · Has a placebo group

Conditions studied: Nonproliferative Diabetic Retinopathy

In brief

The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR).

Key facts

Study ID
NCT03197870
Run by
EyePoint Pharmaceuticals, Inc.
People needed
167
Starts
2017-06-09
Expected to finish
2019-02-09
Last updated by the study team
2023-06-27

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.